Hiba Al Tarrah

Hiba Al Tarrah

Auto-generated profile, based on publicly available information

Hiba Al Tarrah

Department of Pediatric Hematology Oncology and Stem Cell Transplantation, King Fahad Specialist Hospital Dammam, Dammam, Saudi Arabia

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2023 in BJR|Open
Verified
Journal Article
Open access
PDF file
MAMaryam Alhashim
Maryam Alhashim
NANoushin Anan
Noushin Anan
MTMahbubunnabi Tamal
Mahbubunnabi Tamal
HAHibah Altarrah
Hibah Altarrah
SASarah Alshaibani
Sarah Alshaibani
RHRobin Hill
Robin Hill
Background: Wilms tumour, a common paediatric cancer, is difficult to treat in low- and middle-income countries due to limited access to imaging. Artificial intelligence (AI) has been introduced for staging, detecting, and classifying tumours, aiding physicians in decision-making. However, challenges include algorithm accuracy, translation into conventional diagnosis, reproducibility, and reliability. As AI technology advances, radiomics, an AI tool, emerges to extract tumour morphology and stage information. Objectives: This review explores the application of radiomics in Wilms tumour management, including its potential in diagnosis, prognosis, and treatment. Additionally, it discusses the future prospects of AI in this field and potential directions for automation-aided Wilms tumour treatment. Methods: The review analyses various research studies and articles on the use of radiomics in Wilms tumour management. This includes studies on automated deep learning-based classification, interobserver variability in histopathological analysis, and the application of AI in staging, detecting, and classifying Wilms tumours. Results: The review finds that radiomics offers several promising applications in Wilms tumour management, including improved diagnosis: it helps in classifying Wilms tumours from other paediatric kidney tumours, prognosis prediction: radiomic features can be used to predict both staging and response to preoperative chemotherapy, Treatment response assessment: Radiomics can be used to monitor the response of Wilms and to predict the feasibility of nephron-sparing surgery. Conclusions: This review concludes that radiomics has the potential to significantly improve the diagnosis, prognosis, and treatment of Wilms tumours. Despite some challenges, such as the need for further research and validation, AI integration in Wilms tumour management offers promising opportunities for improved patient care. Advances in knowledge: This review provides a comprehensive overview of the potential applications of radiomics in Wilms tumour management and highlights the significant role AI can play in improving patient outcomes. It contributes to the growing body of knowledge on AI-assisted diagnosis and treatment of paediatric cancers.

1 July 2025 in JCO Global Oncology
Verified
Journal Article
Closed access
EBEssra' Al Badarin
Essra' Al Badarin
OCOmar Chamdine
Omar Chamdine
MEMoatasem Elayadi
Moatasem Elayadi
AAAbeer Al-Battashi
Abeer Al-Battashi
MNMohammed Al Nuaimi
Mohammed Al Nuaimi
NANisreen Amayiri
Nisreen Amayiri
PURPOSE: Video teleconferencing in neuro-oncology is feasible and sustainable. The well-established, 20-year long monthly teleconference between King Hussein Cancer Center (KHCC), Jordan, and SickKids, Canada, is an example. Since 2018, several regional centers joined these meetings to discuss their patients' management plans. We aim to evaluate this experience. METHODS: We reviewed the minutes of 56 meetings (2018-2023). Preconference local treatment plans were compared with postconference recommendations. We documented the implementation of recommendations and the impact perceived by the treating oncologists. RESULTS: Two hundred fifty-one patients were discussed: 137 from Jordan and 114 from eight other countries. Four of the 14 participating oncologists had formal pediatric neuro-oncology training. Of the 227 patients (90%), where the local multidisciplinary team had suggested a preconference plan, the teleconference recommendations concurred with the proposed plan in 50% of cases, agreed on it and proposed an alternative option in 18%, and disagreed in 32%. The difference in recommendations mostly affected the proposed treatment modality. In 64% of discordant plans and 50% of alternative plans, the treating team applied the recommendations. The main challenges in applying the recommendations were attributed to patient-related factors (51%), local team consensus on a different plan (26%), or logistic difficulties (23%). The high patient load, longer involvement in teleconferencing, formal neuro-oncology training, and well-established multidisciplinary team helped the KHCC team formulate more concordant plans. CONCLUSION: This experience illustrates the potential benefit for physicians to get an expert opinion on challenging cases. The participating oncologists valued the shared educational experience, especially those related to molecular testing and treatment implications. Joining such regional teleconferences is of particular importance to centers with small patient volume or those lacking a pediatric neuro-oncologist.

1 April 2026 in JCO Global Oncology
Verified
Journal Article
Closed access
HTHiba Al Tarrah
Hiba Al Tarrah
IAIbraheem Abosoudah
Ibraheem Abosoudah
SASami Althubaiti
Sami Althubaiti
RHRawan Hammad
Rawan Hammad
AAAbdulrahman Alsultan
Abdulrahman Alsultan
MKMuhammad Saghir Khan
Muhammad Saghir Khan
The 17th Annual Congress of the Asian Society of Pediatric Oncology (SIOP Asia) was held in Riyadh, Saudi Arabia, from April 12 to 15, 2025, marking its first hosting in the Kingdom. Organized in collaboration with the Saudi Pediatric Hematology Oncology Society and global partners, the congress convened over 500 delegates from 45 countries under the theme “Stronger Together.” The scientific program featured nearly 70 invited speakers across five tracks: hematologic malignancies, solid tumors, neuro-oncology, precision medicine, and survivorship alongside multidisciplinary sessions in surgery, radiation oncology, nursing, and pharmacy. A total of 347 abstracts from 34 countries were submitted; 267 were accepted as posters, and 17 as oral presentations. Education Day, organized through SIOP's Disease-Specific Portal for Learning and Networking (DiSPLeN), provided case-based training to over 200 delegates comprising fellows along with junior and senior multidisciplinary participants emphasizing applicability in low-resource settings. Key congress themes included improving diagnostic equity, access to essential medicines, and strengthening regional research capacity. Presentations highlighted molecularly driven diagnostics such as FOXO1 fusion testing in rhabdomyosarcoma and LOGIC assays for constitutional mismatch repair deficiency, with emphasis on affordable applications in low- and middle-income countries (LMICs). Access to chemotherapy was addressed through the WHO/St Jude Global Platform for Childhood Cancer Medicines, offering sustainable, centralized procurement for LMICs. The need for expanded multicenter clinical trials was underscored, with initiatives such as the Asian Pediatric Hematology and Oncology Group, SIOP's Programme for Advancing Research Capacity, and collaborative tumor boards providing frameworks for progress. Surgical and radiation oncology sessions showcased pragmatic adaptations of advanced technologies, whereas survivorship and genetics sessions highlighted cancer predisposition syndromes and long-term quality-of-life challenges. The Riyadh congress reaffirmed that survival disparities in Asia are driven by addressable inequities. By advancing diagnostics, medicines, registries, and collaborative trials, SIOP Asia and its partners demonstrated a pathway toward narrowing the survival gap.